Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: A systematic review

Research in Developmental Disabilities

Volumn 34, Issue 12, 2013, Pages 4293-4303

  Ward, Frances ^a   Tharian, Priyanka ^b   Roy, Meera ^c   Deb, Shoumitro ^d   Unwin, Gemma L ^b  

^a SOUTHERN HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Birmingham Community Healthcare NHS Trust ^*  (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Autism spectrum conditions; Beta adrenergic blockers; Intellectual disability; Problem behaviours; Propanolol; Self injurious behaviour

Indexed keywords

ACEBUTOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; NADOLOL; OXPRENOLOL; PLACEBO; PROPRANOLOL;

ABSENCE OF SIDE EFFECTS; AGGRESSION; BEHAVIOR DISORDER; BRADYCARDIA; BRONCHOSPASM; CLINICAL EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART RATE; HUMAN; HYPOTENSION; INSOMNIA; INTELLECTUAL IMPAIRMENT; NAUSEA; PULSE RATE; REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

AUTISM SPECTRUM CONDITIONS; BETA ADRENERGIC BLOCKERS; INTELLECTUAL DISABILITY; PROBLEM BEHAVIOURS; PROPANOLOL; SELF-INJURIOUS BEHAVIOUR;

ADRENERGIC BETA-ANTAGONISTS; AGGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; INTELLECTUAL DISABILITY; MENTAL DISORDERS; SELF-INJURIOUS BEHAVIOR; STEREOTYPED BEHAVIOR; TREATMENT OUTCOME;

EID: 84887613610     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2013.08.015     Document Type: Review

References (46)

1. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The aberrant behaviour check list: A behaviour rating scale for the assessment of treatment effects. American Journal of Mental Deficiency 1985, 89:485-491.
2. Baumeister A.A., Sevin J.A. Pharmacologic control of aberrant behaviour in the mentally retarded: Toward a more rational approach. Neuroscience & Biobehavioural Reviews 1990, 14:253-326.
3. Bradley E.A., Ames C.S., Bolton P.F. Psychiatric conditions and behavioural problems in adolescents with intellectual disabilities: Correlates with Autism?. Canadian Journal of Psychiatry 2011, 56(2):102-109.
4. Calamari J.E., McNally R.J., Benson D.S., Babington C.M. Case study: Use of propanolol to reduce aggressive behaviour in a woman who is mentally retarded. Behavioural Interventions 1990, 5(4):287-296.
5. Cohen I.L., Tsiouris J.A., Pfadt A. Effects of long-acting propanolol on agonistic and stereotyped behaviours in a man with pervasive developmental disorder and fragile X syndrome: A double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 1991, 11(6):398-399.
6. Connor D.F. Nadolol for self-injury, overactivity, inattention and aggression in a child with pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology 1994, 4(2):101-111.
7. Connor D.F., Ozbayrak K.R., Benjamin S., Yusheng M.A., Fletcher K.E. A pilot study of nadolol for overt aggression in developmentally delayed individuals. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36(6):826-834.
8. De Leersnyder H., de Blois M.C., Vekemans M., Sidi D., Villain E., Kindermans C., et al. Beta(1)-adrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith-Magenis syndrome. Journal of Medical Genetics 2001, 38(9):586-590.
9. Deb S. Pharmacological interventions. Intellectual disability psychiatry: A practical handbook 2009, 203-222. John Wiley & Sons Ltd., Ealing. A. Hassiotis, D.A. Barron, I. Hall (Eds.).
10. Deb S. Psychopharmacology. Handbook of psychopathology in intellectual disability: research, practice, and policy, autism and child psychopathology series 2013, Springer Science + Business Media, New York, USA, (Chapter, 19), (Series Editor: Johnny L. Matson), pp. 307-324. E. Tsakanikos, J. McCarthy (Eds.).
11. Deb S., Thomas M., Bright C. Mental disorder in adults with intellectual disability. 2: The rate of behaviour disorder among a community based population aged 16 to 64 years. Journal of Intellectual Disability Research 2001, 45:506-514.
12. Deb S., Sohanpal S.K., Soni R., Unwin G., Lenôtre L. The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. Journal of Intellectual Disability Research 2007, 51(10):766-777.
13. Deb S., Chaplin R., Sohanpal S., Unwin G., Soni R., Lenôtre L. The effectiveness of mood stabilisers and antiepileptic medication for the management of behaviour problems in adults with intellectual disability: A systematic review. Journal of Intellectual Disability Research 2008, 52(2):107-113.
14. Deb S., Kwok H., Bertelli M., Salvador-Carulla L., Bradley E., Torr J., et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry 2009, 8(3):181-186.
15. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology & Community Health 1998, 52:377-384.
16. Edelbrock C. Child attention problem rating scale. Attention deficit hyperactivity disorder: A clinical workbook 1991, 49-51. Guilford Press, New York. R.A. Barkley (Ed.).
17. Goyette C.H., Connors C.K., Ulrich R.F. Normative data on revised Connors parent and teacher rating scales. Journal of Abnormal Child Psychology 1978, 6:221-236.
18. Greendyke R.M., Schuster D.B., Wooton J.A. Propanolol in the treatment of assaultive patients with organic brain disease. Journal of Clinical Psychopharmacology 1984, 4:283-285.
19. Greendyke R.M., Kanter D.R., Schuster D.B., Verstreate S., Wooton J. Propanolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study. Journal of Nervous and Mental Disease 1986, 174:290-294.
20. Guy W. Clinical global impressions. ECDEU assessment manual for psychopharmacology, revised 1976, National Institute of Mental Health, Rockville, MD.
21. Harris R.P., Helfand M., Woolf S.H., Lohr K.N., Mulrow C.D., Teutsch S.M., et al. Methods work group, third US preventive services task force (2001) current methods of the US preventive services task force: A review of process. American Journal of Preventive Medicine 2001, (3 Suppl.):21-35.
22. Haspel T. Beta blockers and the treatment of aggression. Harvard Review of Psychiatry 1995, 2(5):274-281.
23. Hiremath A., Gangavati S., Bhaumik S., Kiani R., Devapriam J. A study on the use of propanolol in managing behavioural problems in people with intellectual disability. The British Journal of Developmental Disabilities 2010, 56(2):147-154.
24. Kastner T., Burlingham K., Friedman D.L. Metorprolol for aggressive behaviour in persons with mental retardation. American Family Physician 1990, 42(6):1585-1589.
25. Knabe R., Bovier B. Pharmacological treatment of extreme self-injurious behaviour in autism. European Psychiatry 1992, 7:297-298.
26. Kuperman S., Stewart M.A. Use of propanolol to decrease aggressive outbursts in younger patients. Psychosomatics 1987, 28(6):315-320.
27. Lader M. Beta adrenoceptor antagonists in neuropsychiatry: An update. Journal of Clinical Psychiatry 1988, 49(6):213-223.
28. Lang C., Remington D. Treatment with propanolol of severe self-injurious behaviour in a blind, deaf, retarded adolescent. Journal of the American Academy of Child and Adolescent Psychiatry 1994, 33(2):265-269.
29. Luchins D.J., Dojka M.S. Lithium and propanolol in aggression and self-injurious behaviour in the mentally retarded. Psychopharmacology Bulletin 1989, 25(3):372-375.
30. Markowitz J.S., Wells B.G., Carson W.H. Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy 1995, 19(6):603-609.
31. Morgan J., Tyrer P. Treating somatic symptoms of anxiety. CNS Drugs 1994, 1:427-434.
32. Morgan C.N., Roy M., Nasr A., Chance P., Hand M., Mlele T.J.J., et al. A community survey establishing the prevalence rate of autistic disorder in adults with learning disability. Psychiatric Bulletin 2002, 26:127-130.
33. Polakoff S., Sorgi P., Ratey J.J. The treatment of impulsive aggressive behaviour with nadolol. Journal of Clinical Psychopharmacology 1986, 2(6):114.
34. Ratey J.J., Lindem K.J. Beta blockers as primary treatment for aggression and self-injury in the developmentally disabled. Mental retardation: Developing pharmacotherapies 1991, 51-81. American Psychiatric Press. J.J. Ratey (Ed.).
35. Ratey J.J., Mikkelsen E.J., Smith G.B., Upadhyaya A., Zuckerman S., Martelli D., et al. Beta blockers in the severely and profoundly mentally retarded. Journal of Clinical Psychopharmacology 1986, 6(2):103-107.
36. Ratey J.J., Bemporad J., Sorgi P., Bick P., Polakoff S., O'Driscoll G., et al. Brief report: Open trial effects of beta-blockers on speech and social behaviours in 8 autistic adults. Journal of Autism and Developmental Disorders 1987, 17(3):439-446.
37. Ratey J.J., Greenberg M.S., Lindem K.J. Combination of treatments for attention deficit hyperactivity disorder in adults. Journal of Nervous and Mental Disease 1991, 179:699-701.
38. Ratey J.J., Sorgi P., O'Driscoll G.A., Sands S., Daehler M.L., Fletcher J.R., et al. Journal of Clinical Psychiatry 1992, 53(2):41-46.
39. Ruedrich S.L. Beta-adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. American Journal of Mental Retardation 1990, 95:110-119.
40. Ruedrich S., Erhardt L. Beta-adrenergic blockers in mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews 1999, 5:290-298.
41. Sadavoy J., Lanctôt K.L., Deb S. Management of behavioural and psychological symptoms of dementia and acquired brain injury. Cambridge textbook of effective treatments in psychiatry 2008, 187-216. Cambridge University Press, Cambridge. P. Tyrer, K.R. Silk (Eds.).
42. Silver J.M., Yudofsky S.C. Overt aggression scale: Overview and guiding principles. The Journal of Neuropsychiatry and Clinical Neurosciences 1991, 3(2):s22-s29.
43. Silver J.M., Yudofsky S.C., Kogan M., Katz B.L. Elevation of thioridazine plasma levels by propanolol. American Journal of Psychiatry 1986, 143(10):1290-1292.
44. Unwin G., Deb S. The use of medication for the management of behaviour problems in adults with intellectual disabilities: A clinicians' consensus survey. American Journal on Mental Retardation 2008, 113(1):19-31.
45. Unwin G.L., Deb S. Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic review. Research in Developmental Disabilities 2011, 32:2121-2133.
46. Williams D.T., Hehl R., Yudovsky S., Adams D., Roseman B. The effect of propanolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. Journal of the American Academy of Child and Adolescent Psychiatry 1982, 21:129-135.